Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA9 | Q16790 | 3/20 | 0.48 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.46 |
| ▸ | FAAH | O00519 | 7/20 | 0.42 |
| ▸ | JMJD6 | Q6NYC1 | 1/20 | 0.42 |
| ▸ | MGLL | Q99685 | 3/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | BCL2 | P10415 | 1/20 | 0.39 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.39 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5268800 | 0.89 | CA9 (0.50) | CA9CHRNA7FAAHMGLLKMT2A | |
| SCHEMBL5268253 | 0.88 | CA9 (0.48) | CA9CHRNA7FAAHJMJD6MGLL | |
| SCHEMBL2918939 | 0.87 | CA9 (0.63) | CA9CHRNA7FAAHMGLLKMT2A | |
| SCHEMBL2915848 | 0.87 | CA9 (0.63) | CA9CHRNA7FAAHJMJD6MGLL | |
| SCHEMBL5265892 | 0.86 | RPA1 (0.52) | KMT2ABCL2MDM2MCL1 | |
| SCHEMBL2921056 | 0.86 | CA9 (0.54) | CA9CHRNA7FAAHTP53BCL2 | |
| SCHEMBL2917961 | 0.86 | CA9 (0.54) | CA9CHRNA7FAAHJMJD6BCL2 | |
| SCHEMBL14504359 | 0.86 | CA9 (0.54) | CA9CHRNA7FAAHJMJD6MGLL | |
| SCHEMBL5268833 | 0.85 | CA9 (0.43) | CA9CHRNA7FAAHJMJD6KMT2A | |
| SCHEMBL5267834 | 0.85 | CA9 (0.47) | CA9CHRNA7FAAHJMJD6MGLL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070254881-A1 | Pyrazole Derivative | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-11-01 | — | — | US | disclosed |
| US-20070219210-A1 | Amidopyrazole Derivative | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-09-20 | — | — | US | disclosed |
| EP-1785418-A1 | PYRAZOLE DERIVATIVE | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-05-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070254881-A1 | Pyrazole Derivative | PTGER1, PTGS1, PTGER2 | CA9 3231/4885CHRNA7 4207/4885FAAH 1657/4885 |
| US-20070219210-A1 | Amidopyrazole Derivative | PTGER1, PTGS1, PTGER2 | CA9 3499/4885CHRNA7 4667/4885FAAH 63/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.